DT-diaphorase prevents aminochrome-induced alpha-synuclein oligomer formation and neurotoxicity

Toxicological Sciences

Volumn 145, Issue 1, 2015, Pages 37-47

  Muñoz, Patricia ^a   Cardenas, Sergio ^a,b   Huenchuguala, Sandro ^a   Briceño, Andrea ^a   Couve, Eduardo ^c   Paris, Irmgard ^a,d   Segura Aguilar, Juan ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSIDAD CENTRAL DE CHILE   (Chile)

^c UNIVERSIDAD DE VALPARAÍSO   (Chile)

^d UNIVERSIDAD SANTO TOMÁS   (Chile)

Author keywords

Alpha synuclein; Aminochrome; Dopamine; Dopaminergic neurons; Neuroprotection; NQO1; Oligomers; Parkinsons's disease

Indexed keywords

ALPHA SYNUCLEIN; AMINOCHROME; DOPAMINE DERIVATIVE; OLIGOMER; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SMALL INTERFERING RNA; THIOFLAVINE; UNCLASSIFIED DRUG; BENZOPYRAN DERIVATIVE; BIOPOLYMER; NQO1 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CIRCULAR DICHROISM; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FLOW CYTOMETRY; FLUORESCENCE; IN VITRO STUDY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; RAT; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; CELL LINE; DRUG EFFECTS; HUMAN; METABOLISM; NERVOUS SYSTEM;

ALPHA-SYNUCLEIN; BENZOPYRANS; BIOPOLYMERS; CELL LINE; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); NERVOUS SYSTEM;

EID: 84929666498     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfv016     Document Type: Article

References (42)

1. Aguirre, P., Urrutia, P., Tapia, V., Villa, M., Paris, I., Segura-Aguilar, J., and Núñez, M. T. (2012). The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1. Biometals 25, 795-803.
2. Arriagada, C., Paris, I., Sanchez de las Matas, M. J., Martinez-Alvarado, P., Cardenas, S., Castaneda, P., Graumann, R., Perez-Pastene, C., Olea-Azar, C., Couve, E., et al. (2004). On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation:mitochondria damage, necrosis, and hydroxyl radical formation. Neurobiol. Dis. 16, 468-477.
3. Aytan, N., Choi, J. K., Carreras, I., Kowall, N. W., Jenkins, B. G., and Dedeoglu, A. (2013). Combination therapy in a transgenic model of Alzheimer's disease. Exp. Neurol. 250, 228-238.
4. Bae, S. Y., Kim, S., Hwang, H., Kim, H. K., Yoon, H. C., Kim, J. H., Lee, S., and Kim, T. D. (2010). Amyloid formation and disaggregation of α-synuclein and its tandem repeat (α-TR). Biochem. Biophys. Res. Commun. 400, 531-536.
5. Bisaglia, M., Mammi, S., and Bubacco, L. (2007). Kinetic and structural analysis of the early oxidation products of dopamine:analysis of the interactions with alpha-synuclein. J. Biol. Chem. 282, 15597-15605.
6. Bisaglia, M., Soriano, M. E., Arduini, I., Mammi, S., and Bubacco, L. (2010). Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. Biochim. Biophys. Acta 1802, 699-706.
7. Choi, B. K., Choi, M. G., Kim, J. Y., Yang, Y., Lai, Y., Kweon, D. H., Lee, N. K., and Shin, Y. K. (2013). Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc. Natl. Acad. Sci. U.S.A. 110, 4087-4092.
8. Colla, E., Jensen, P. H., Pletnikova, O., Troncoso, J. C., Glabe, C., and Lee, M. K. (2012). Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J. Neurosci. 32, 3301-3305.
9. Conway, K. A., Rochet, J. C., Bieganski, R. M., and Lansbury, P.T., Jr (2001). Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 1346-1349.
10. Danzer, K. M., Kranich, L. R., Ruf, W. P., Cagsal-Getkin, O., Winslow, A. R., Zhu, L., Vanderburg, C. R., and McLean, P. J. (2012). Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 24, 42.
11. Fecchio, C., De Franceschi, G., Relini, A., Greggio, E., Dalla Serra, M., Bubacco, L., and Polverino de Laureto, P. (2013). α-Synuclein oligomers induced by docosahexaenoic acid affect membrane integrity. PLoS One, 8, e82732.
12. Gruden, M. A., Davydova, T. V., Narkevich, V. B., Fomina, V. G., Wang, C., Kudrin, V. S., Morozova-Roche, L. A., and Sewell, R. D. (2014). Intranasal administration of alpha-synuclein aggregates:a Parkinson's disease model with behavioural and neurochemical correlates. Behav. Brain Res. 263, 158-168.
13. Ha, Y., Yang, A., Lee, S., Kim, K., Liew, H., Suh, Y. H., Park, H. S., and Churchill, D. G. (2014). Facile "stop codon" method reveals elevated neuronal toxicity by discrete S87p-α-synuclein oligomers. Biochem. Biophys. Res. Commun. 443, 1085-1091.
14. Hong, D. P., Fink, A. L., and Uversky, V. N. (2008). Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. J. Mol. Biol. 383, 214-223.
15. Huenchuguala, S., Muñoz, P., Zavala, P., Villa, M., Cuevas, C., Ahumada, U., Graumann, R., Nore, B. F., Couve, E., Mannervik, B., et al. (2014). Glutathione transferase mu 2 protects glioblastoma cells against aminochrome toxicity by preventing autophagy and lysosome dysfunction. Autophagy 10, 618-630.
16. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., and Glabe, C. G. (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489.
17. Konno, M., Hasegawa, T., Baba, T., Miura, E., Sugeno, N., Kikuchi, A., Fiesel, F. C., Sasaki, T., Aoki, M., Itoyama, Y., and Takeda, A. (2012). Suppression of dynamin GTPase decreases α-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy. Mol. Neurodegener. 7, 38.
18. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T., and Lansbury, P.T., Jr (2002). Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291.
19. LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M.G., and Selkoe, D. J. (2005). Dopamine covalentlymodifies and functionally inactivates parkin. Nat. Med. 11, 1159-1161.
20. Li, H. T., Lin, D. H., Luo, X. Y., Zhang, F., Ji, L. N., Du, H. N., Song, G.Q., Hu, J., Zhou, J.W., and Hu, H.Y. (2005). Inhibition of alpha- synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration. FEBS J. 272, 3661-3672.
21. Lozano, J., Muñoz, P., Nore, B. F., Ledoux, S., and Segura-Aguilar, J. (2010). Stable expression of short interfering RNA for DTdiaphorase induces neurotoxicity. Chem. Res. Toxicol. 23, 1492-1496.
22. Martin, Z. S., Neugebauer V., Dineley, K. T., Kayed, R., Zhang, W., Reese, L. C., and Taglialatela, G. (2012). α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. J. Neurochem. 120, 440-452.
23. Mosharov, E. V., Staal, R. G., Bové, J., Prou, D., Hananiya, A., Markov, D., Poulsen, N., Larsen, K. E., Moore, C. M., Troyer, M. D., et al. (2006). Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J. Neurosci. 26, 9304-9311.
24. Muñoz, P., Huenchuguala, S., Paris, I., and Segura-Aguilar, J. (2012). Dopamine oxidation and autophagy. Parkinsons Dis. 2012, 920953.
25. Norris, E. H., Giasson, B. I., Hodara, R., Xu, S., Trojanowski, J. Q., Ischiropoulos, H., and Lee, V. M. (2005). Reversible inhibition of alpha-synuclein fibrillization by dopaminochromemediated conformational alterations. J. Biol. Chem. 280, 21212-21219.
26. Paris, I., Lozano, J., Cardenas, S., Perez-Pastene, C., Saud, K., Fuentes, P., Caviedes, P., Dagnino-Subiabre, A., Raisman-Vozari, R., Shimahara, T., et al. (2008). The catecholaminergic RCSN-3 cell line: a model to study dopamine metabolism. Neurotox. Res. 13, 221-230.
27. Paris, I., Lozano, J., Perez-Pastene, C., Muñoz, P., and Segura-Aguilar, J. (2009). Molecular and neurochemical mechanisms in PD pathogenesis. Neurotox. Res. 16, 271-279.
28. Paris, I., Perez-Pastene, C., Cardenas, S., Iturriaga-Vasquez, P., Muñoz, P., Couve, E., Caviedes, P., and Segura-Aguilar, J. (2010). Aminochrome induces disruption of actin, alpha-, and beta-tubulin cytoskeleton networks in substantia-nigraderived cell line. Neurotox. Res. 18, 82-92.
29. Puschmann, A. (2013). Monogenic Parkinson's disease and parkinsonism:clinical phenotypes and frequencies of known mutations. Parkinsonism Relat. Disord. 19, 407-415.
30. Scarlata, S., and Golebiewska, U. (2014). Linking alpha-synuclein properties with oxidation: a hypothesis on a mechanism underling cellular aggregation. J. Bioenerg. Biomembr. 46, 93-98.
31. Schultzberg, M., Segura-Aguilar, J., and Lind, C. (1988). Distribution of DT diaphorase in the rat brain: biochemical and immunohistochemical studies. Neuroscience 27, 763-766.
32. Segura-Aguilar, J., Paris, I., Muñoz, P., Ferrari, E., Zecca, L., and Zucca, F. A. (2014). Protective and toxic roles of dopamine in Parkinson's disease. J. Neurochem. 129, 898-915.
33. Segura-Aguilar, J., and Lind, C. (1989). On the mechanism of the Mn3({thorn})-induced neurotoxicity of dopamine: prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase. Chem. Biol. Interact. 72, 309-324.
34. Segura-Aguilar, J., Kajser, R., and Lind, C. (1992). Separation and characterization of isoforms of DT-diaphorase from rat liver cytosol. Biochim. Biophys. Acta 1120, 33-42.
35. Segura-Aguilar, J., Metodiewa, D., and Welch, C. J. (1998). Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim. Biophys. Acta 1381, 1-6.
36. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., and Goedert, M. (1998). Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 95, 6469-6473.
37. Sulzer, D., Bogulavsky, J., Larsen, K. E., Behr, G., Karatekin, E., Kleinman, M. H., Turro, N., Krantz, D., Edwards, R. H., Greene, L. A., and Zecca, L. (2000). Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. U.S.A. 97, 11869-11874.
38. Van Laar, V. S., Mishizen, A. J., Cascio, M., and Hastings, T. G. (2009). Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol. Dis. 34, 487-500.
39. Vekrellis, K., Xilouri, M., Emmanouilidou, E., and Stefanis, L. (2009). Inducible over-expression of wild type alpha-synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death. J. Neurochem. 109, 1348-1362.
40. Volles, M. J., and Lansbury, P.T., Jr (2003). Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42, 7871-7878.
41. Weingarten, P., and Zhou, Q. Y. (2001). Protection of intracellular dopamine cytotoxicity by dopamine disposition and metabolism factors. J. Neurochem. 77, 776-785.
42. Zafar, K. S., Siegel, D., and Ross, D. (2006). A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4- dihydroxyphenylacetic acid in proteasomal inhibition. Mol. Pharmacol. 70, 1079-1086.